Citalopram - Adverse effects
Research News and Information

Saturday, November 21, 2009

Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients.

30 Aug 2009 OBJECTIVES: Suicidal ideation is an uncommon but worrisome symptom than can emerge during antidepressant treatment. We have described earlier the association between treatment-emergent suicidal ideation (TESI) and markers in genes encoding glutamate ... Read more...

Depressive disorders in stroke patients.

30 Aug 2009 Post-stroke depression is a serious complication of ischemic stroke which has negative influences on patients' quality of life and on recovery from symptoms and the prognosis of the underlying disease. We report here a study of the efficacy of ... Read more...

Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial.

29 Jun 2009 OBJECTIVE: This article presents the results from a prospective, randomized, double-blind, placebo-controlled trial of escitalopram in adolescent patients with major depressive disorder. METHOD: Male and female adolescents (aged 12-17 years) with ... Read more...

Latest indexed articles for 'Citalopram - Adverse effects'

These are the very latest articles for this heading:

• Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. 30 Oct 2009
• Drug fails to subdue repetitive behavior in children with autism spectrum disorders. 29 Sep 2009
• Genetic studies of drug response and side effects in the STAR*D study, part 2. 30 Aug 2009
• Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 30 Aug 2009
• Depressive disorders in stroke patients. 30 Aug 2009
• Antidepressants as hydrobromide salts: are they a cause for concern? 30 Jul 2009
• Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. 29 Jun 2009
• Antidepressant drugs in cancer patients: the case of escitalopram. 29 Jun 2009
• Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. 29 Jun 2009
• Two cases of herpes zoster, occurring 4 and 6 weeks after the initiation of citalopram treatment. 24 Jun 2009
• Acute dyskinesia and extrapyramidal disorder in a child after ingestion of escitalopram. 30 May 2009
• Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. 30 May 2009
• Depression and cognitive complaints following mild traumatic brain injury. 30 May 2009
• Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. 30 May 2009
• Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. 3 May 2009
• Citalopram-induced bleeding due to severe thrombocytopenia. 29 Apr 2009
• Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. 29 Apr 2009
• Quality of life measurement in antidepressant trials. Is there an added value? 26 Apr 2009
• Reversible cerebral vasoconstriction syndrome: case report. 14 Apr 2009
• Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Citalopram'

Definition: A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.

Chemical name: 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-

Registry Number: 59729-33-8

Descriptor UI: D015283

Alternative terms: Citalopram; Cytalopram; Lu-10-171; Lu10171; Escitalopram; Lexapro;

Allowable Qualifiers: therapeutic use; toxicity; urine; chemistry; contraindications; agonists; administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution;

Pharmacological Action: Antidepressive Agents, Second-Generation; Serotonin Uptake Inhibitors;

Tree Number: D02.092.831.170; D02.626.320; D03.383.312.225.187; D03.438.127.187;

History Note: 1989; for ESCITALOPRAM use CITALOPRAM (NM) 2001-2002